Table 2 Demographic and clinical features of NMO and TBM patients
From: Association between neuromyelitis optica and tuberculosis in a Chinese population
|  | NMO n = 88 | TBM | ||
|---|---|---|---|---|
Total n = 92 | TBM-MY n = 10 | TBM-ON n = 2 | ||
Sex ratio, F/M | 71/7 | 40/52 | 3/7 | 1/1 |
Age, mean ± SD, years | 35.3 ± 14.4 | 33.5 ± 18.6 | 34.1 ± 13.9 | 19, 41 |
Relapse of myelitis, n(%) | 66/88 (75.0%) | -- | 0/6 (0) | -- |
CSF | Â | Â | Â | Â |
Pleocytosis, n(%) | 16/88 (18.2%) | 92/92 (100.0%) | 10/10 (100%) | 2/2 (100%) |
Increased protein level, n(%) | 14/88 (15.9%) | 92/92 (100.0%) | 10/10 (100%) | 2/2 (100%) |
Decreased glucose level, n(%) | 1/88 (1.1%) | 92/92 (100.0%) | 10/10 (100%) | 2/2 (100%) |
TB-antibody positivity, n(%) | 0/45 (0) | 27/92 (29.3%) | 3/10 (30%) | 0/2 (0) |
Mycobacterium tuberculosis, n(%) | 0/45 (0) | 0/92 (0) | 0/10 (0) | 0/2 (0) |
Seropositive NMO-IgG, n(%) | 55/67 (82.1%) | 0/5 (0) | 0/3 (0) | 0/1 (0) |
Spinal MRI | Â | Â | Â | Â |
Linear lesions, n(%) | 41/88 (46.6%) | -- | 0/7 (0) | -- |
LESCLs, n(%) | 65/88 (73.9%) | -- | 1/7 (14.3%) | -- |
Central or holocord involvement, n(%) | 65/88 (73.9%) | -- | 1/7 (14.3%) | -- |
Tuberculoma, n(%) | 0/88 (0) | -- | 3/7 (42.9%) | -- |
Meningeal enhancement, n(%) | 7/88 (8.0%) | -- | 4/7 (57.1%) | -- |
Follow-up duration, median (range), months | 28.5 (12–106) | 14.5 (5–96) | 18.0 (6–84) | 24, 17 |